Bayer Aktiengesellschaft (FRA:BAYN)
Germany · Delayed Price · Currency is EUR | Market Cap | 38.54B +67.5% |
| Revenue (ttm) | 45.24B -2.9% |
| Net Income | -2.16B |
| EPS | -2.19 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.77 |
| Dividend | 0.11 (0.29%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 1,892,865 |
| Average Volume | 20,424 |
| Open | 39.04 |
| Previous Close | 39.23 |
| Day's Range | 38.49 - 39.21 |
| 52-Week Range | 23.27 - 49.76 |
| Beta | n/a |
| RSI | 51.48 |
| Earnings Date | May 12, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial StatementsNews
Bayer to present new data across oncology portfolio
Bayer (BAYRY) announced that new data from studies across their oncology portfolio will be presented at the upcoming 2026 American Society of Clinical Oncology, ASCO, Annual Meeting, taking place in…
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer to Present New Data Across Oncology Portfolio.
Bayer announces Priority Review designation for Kerendia
Bayer (BAYRY) announced that the FDA accepted its supplemental new drug application and granted Priority Review designation for Kerendia, which is being investigated for the treatment of adults with t...
Bayer says FDA grants priority review designation for finerenone
Bayer said on Thursday that the U.S. Food and Drug Administration had accepted its supplemental New Drug Application for finerenone and granted priority review designation.
Bayer's KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review ...
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Bayer upgraded to Buy from Hold at DZ Bank
DZ Bank upgraded Bayer (BAYRY) to Buy from Hold with a EUR 51 price target
Bayer granted priority review for asundexian by FDA
Bayer (BAYRY) announced that the FDA has accepted the company’s new drug application and granted priority review designation for its investigational oral Factor XIa inhibitor, asundexian, for the prev...
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT'S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) and granted Priori...
Bayer agrees to pay $133 million for PCB cleanup in two states
Bayer's Monsanto unit on Monday said it would pay at least $133 million to settle Michigan and Rhode Island's claims that the company contaminated the states' natural resources with toxic chemicals ...
Bayer announces HYRNUO sNDA granted Priority Review status by FDA
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has granted HYRNUO Priority Review status for the first-line treatment of adult patients with locally advanced or metastatic non-smal...
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
WHIPPANY, N.J.--(BUSINESS WIRE)--Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol® in Motion, a camp...
Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum
Bayer Aktiengesellschaft ETR: BAYN executives said the company's Crop Science division remains on track with a five-year plan centered on cost savings, margin expansion and a slate of product launches...
Bayer Aktiengesellschaft Transcript: 21st Annual Global Farm to Market Conference
A five-year strategy is on track, emphasizing margin expansion, cost savings, and a robust innovation pipeline with major product launches planned through 2029. Market dynamics remain stable in North America and Brazil, while global uncertainties and supply chain pressures persist. Legal progress on glyphosate litigation and new biofuel partnerships further shape the outlook.
Bayer launches 2026 campaign to expand food access with Luke Bryan
Bayer (BAYRY) and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America, with Bayer…
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America...
Bayer Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% sales growth and higher EPS, driven by Crop Science and Consumer Health, while Pharma remained flat. Litigation settlements and regulatory clarity efforts progressed, and the full-year outlook was confirmed despite FX and geopolitical risks.
Bayer Aktiengesellschaft Quarterly report: Q1 2026
Bayer Aktiengesellschaft has published its Q1 2026 quarterly earnings report on May 12, 2026.
Bayer Aktiengesellschaft Earnings release: Q1 2026
Bayer Aktiengesellschaft released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Bayer Aktiengesellschaft Slides: Q1 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Bayer Aktiengesellschaft Q1 Earnings Call Highlights
Bayer Aktiengesellschaft ETR: BAYN reported first-quarter 2026 results that management said were in line with expectations, as growth in Crop Science and Consumer Health offset flat performance in Pha...
Bayer Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% sales growth and a 13% rise in core EPS, driven by strong Crop Science performance and non-recurring licensing income. Litigation-related cash outflows weighed on free cash flow, but full-year guidance is reaffirmed amid ongoing regulatory and geopolitical risks.
Bayer Aktiengesellschaft Quarterly report: Q1 2026
Bayer Aktiengesellschaft has published its Q1 2026 quarterly earnings report on May 12, 2026.
Bayer Aktiengesellschaft Earnings release: Q1 2026
Bayer Aktiengesellschaft released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Bayer Net Profit Surges Driven by Growth in Agricultural Division
The group's net profit was aided by a gain from the sale of an antibiotics business and stronger underlying earnings at its agricultural division.